
ACE-031 (ActRIIB-Fc)
by Ponyon
ACE-031 is an experimental ActRIIB-Fc fusion protein that functions as a soluble activin type II receptor-related research molecule, studied for its interactions with myostatin (GDF-8), activins, and other TGF-β superfamily ligands involved in skeletal muscle growth and muscle tissue homeostasis.
SKU ACE031AC-5MG_10 · 30-day returns
ACE-031 is an experimental recombinant fusion protein consisting of the extracellular domain of Activin Type IIB Receptor (ActRIIB) fused to an immunoglobulin Fc domain. Unlike conventional short-chain research peptides, ACE-031 is more accurately characterized as an ActRIIB-Fc fusion protein.
ActRIIB interacts with several members of the TGF-β superfamily, including myostatin (GDF-8) and certain activins. These signaling pathways are closely associated with skeletal muscle growth, muscle tissue homeostasis, cellular differentiation, and related biological processes.
In life science research, ACE-031 is investigated in connection with myostatin/ActRIIB signaling, activin-related pathways, skeletal muscle biology, regulation of muscle growth, and TGF-β superfamily signaling. It can also serve as a research tool for studying ligand-receptor interactions and their downstream biological effects.
ACE-031 has previously undergone human clinical investigation but has not become an approved therapeutic product. It should therefore not be represented as having established muscle-building or performance-enhancing effects in humans.
Free standard shipping on orders over $50 to the US, Canada, Mexico and Europe. Orders ship within 1 business day.
Not happy? Return it within 30 days for a full refund, even if opened.
Reviews
No reviews yet
Be the first to review this product.
Complete your routine
* These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Consult your physician before use if you are pregnant, nursing, taking medication or have a medical condition.







